Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2002-08-20
2008-09-23
Le, Long V. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C436S501000, C436S811000
Reexamination Certificate
active
07427490
ABSTRACT:
The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. In a particular aspect, patient samples are analyzed for the presence or amount of a panel of markers comprising one or more specific markers for cerebral injury and one or more non-specific markers for cerebral injury. In an alternative aspect, samples are analyzed for B-type natriuretic peptide. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.
REFERENCES:
patent: 4447545 (1984-05-01), DeFazio et al.
patent: 5114923 (1992-05-01), Seilhamer et al.
patent: 5290678 (1994-03-01), Jackowski
patent: 5294537 (1994-03-01), Batt
patent: 5350842 (1994-09-01), Norgard
patent: 5352587 (1994-10-01), Chang et al.
patent: 5422393 (1995-06-01), Bricker et al.
patent: 5480792 (1996-01-01), Buechler et al.
patent: 5482935 (1996-01-01), Adelman et al.
patent: 5525524 (1996-06-01), Buechler et al.
patent: 5631171 (1997-05-01), Sandstrom et al.
patent: 5679526 (1997-10-01), Buechler et al.
patent: 5683885 (1997-11-01), Kieback
patent: 5690103 (1997-11-01), Groth et al.
patent: 5786163 (1998-07-01), Hall
patent: 5824799 (1998-10-01), Buechler et al.
patent: 5851776 (1998-12-01), Valkirs
patent: 5885527 (1999-03-01), Buechler
patent: 5922615 (1999-07-01), Nowakowski et al.
patent: 5939272 (1999-08-01), Buechler et al.
patent: 5947124 (1999-09-01), Buechler et al.
patent: 5955377 (1999-09-01), Maul et al.
patent: 5985579 (1999-11-01), Buechler et al.
patent: 6019944 (2000-02-01), Buechler
patent: 6057098 (2000-05-01), Buechler et al.
patent: 6099469 (2000-08-01), Armstrong et al.
patent: 6113855 (2000-09-01), Buechler et al.
patent: 6117644 (2000-09-01), DeBold
patent: 6124430 (2000-09-01), Mischak et al.
patent: 6143576 (2000-11-01), Buechler
patent: 6235489 (2001-05-01), Jackowski
patent: 6268223 (2001-07-01), Cornell-Bell et al.
patent: 6309888 (2001-10-01), Holvoet et al.
patent: 6443889 (2002-09-01), Groth et al.
patent: 6495519 (2002-12-01), He et al.
patent: 6586244 (2003-07-01), Reinhard
patent: 6627457 (2003-09-01), Pandian et al.
patent: 6670138 (2003-12-01), Gonzalez-Zulueta et al.
patent: 6828107 (2004-12-01), Asada et al.
patent: 2002/0052000 (2002-05-01), Parthasarathy et al.
patent: 2002/0106708 (2002-08-01), Thomas et al.
patent: 2003/0022235 (2003-01-01), Dahlen et al.
patent: 2004/0072805 (2004-04-01), Warren et al.
patent: 2004/0167341 (2004-08-01), Haffner et al.
patent: 2005/0181386 (2005-08-01), Diamond et al.
patent: 2005/0244902 (2005-11-01), Gotze et al.
patent: WO 00/18801 (2000-04-01), None
patent: WO 01/18801 (2000-04-01), None
patent: WO 00/52476 (2000-09-01), None
patent: WO 00/52476 (2000-09-01), None
patent: WO 01/14885 (2001-03-01), None
patent: WO 01/16599 (2001-03-01), None
patent: WO 01/42793 (2001-06-01), None
patent: WO 02/083913 (2002-10-01), None
patent: WO 02/089657 (2002-11-01), None
patent: WO 03/002553 (2003-01-01), None
Yakoviev et al., Activation of CPP32-Like Caspases Contributes to Neuronal Apoptosis and Neurological Dysfunction after Traumatic Brain Injury, The Journal of Neuroscience, Oct. 1, 1997, 17 (19): 7415-7424.
Huttunen et al., Coregulation of Neurite Outgrowth and Cell Survival by Amphoterin and S100 Proteins through Receptor for Advanced glycation End Products (RAGE) Activation., Journ. of Biological Chem. vol. 275, Dec. 22, 2000, pp. 40096-40105.
Mussack et al., early cellular brain damage and systemic inflammatory response after cardiopulmonary resuscitation or isolated sever ehad trauma, Resuscitation, (May 2001) vol. 49, No. 2, pp. 193-199.
Harter et al., Caspase-3 activity is present in cerebrospinal fluid from patients with traumatic brain injury, Journal of Neuroimmunology 121 (2001) 76-78.
Webster's II New Riverside University Dictionary, 1994, by Houghton Mifflin Company, p. 1212.
Vander et al., Human Physiology by McGraw-Hill, Sixth Edition, 1994, pp. 214, 215 and 230.
Mussack et al., Early cellular brain damage and systemic inflammatory response after cardiopulmonary resuscitation or isolated severe head trauma, Resuscitation, vol. 40, Issue 2, May 2001, pp. 193-199.
Tarkowski et al., Intrathecel release an pro-and anti-inflammatory cytokines during stroke, Clin Exp Immunol 1997; 110: pp. 492-499.
Feinberg et al., “Guidelines for the Management of Transient Ischemic Attacks.” Stroke, 25(6): 1320-1335, Jun. 1994.
Herrmann et al., “Release of Glial tissue-specific proteins after acute stroke: A comparison analysis of serum concentrations of protein S-100B and Glial fibrillary acidic protein.” Stroke, 31:2670-2677, 2000.
Napoli et al., “C-reactive protein in ischemic stroke: An independent prognostic factor.” Stroke, 32:917-924, 2001.
Strand et al., “Brains and plasma proteins in spinal fluid as markers for brain damage and severity of stroke.” Stroke: 15(1): 138-144, 1994.
Aggarwal et al., “Evaluation of serum lipid protein and cardiac enzyme changes in cerebrovascular accidents,” JIMA, 93:331-332, 1995.
Akiyama et al., “Changes in serum concentrations of matrix metalloproteins, tissue inhibitors of metallo proteinases and Type IV collagen in patients with various types of glomerulonephritis,” Res. Commun. In Mol. Path. and Pharm., 95(2): 115-128, 1997.
Albrecht et al., “Detection of circulating tissue factor VII in a normal population,” Thrombosis and Haemostasis, 75(5): 772-7, 1996.
Albrechtsen and Bock, “Quantification of glial fibrillary acidic protein (GFAP) in human body fluids by means of Elisa employing a monoclonal antibody.” Journal of Neuroimmunology, 8:301-309, 1985.
Austgulen et al., “Increased maternal plasma levels of soluble adhesion in molecules (ICAM-1, VCAM-1, E-selectin) in preeclampsia,” Eur. J. Obstet. Gynecol. Reprod. Biol., 71:53-58, 1997.
Banks et al., “Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies,” Br. J. Cancer, 68:122-124, 1993.
Bates et al., “Neurotrophin-3 promotes cell death induced in cerebral ischemia, oxygen-glucose deprivation, and oxidative stress: possible involvement of oxygen free radicals,” Neurobiology of Disease, :24-37, 2002.
Benamer et al., “Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris,” Am. J. Cardiol., 82:845-850, 1998.
Berendes et al., “Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage,” Lancet, 349:245-249, 1997.
Bialik et al., “Myocyte apoptosis during acute myocardinal infarction in the mouse localized to hypoxic regions but occurs independently of p53,” J.Clin.Invest., 100(6): 1363-1372, 1997.
Biasucci et al., “Elevated levels of interleukin-6 in unstable angina,” Circulation, 94:874-877,1996.
Biasucci et al., “Episodic activation of the coagulation system in unstable angina does not elicit an acute phase reaction,” Am. J. of Cardiol., 77:85-87, 1996.
Biasucci et al., “Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events,” Circulation, 90:2079-2084, 1999.
Bitsch et al., “A longitudinal prospective study of soluble adhesion molecules in acute stroke,” Stroke, 29:2129-2135, 198.
Blankaert et al., “Constitutive release of metalloproteinase-9 (92-kd Type IV col
Buechler Kenneth F.
Dahlen Jeffrey R.
Kirchick Howard J.
Valkirs Gunars E.
Biosite Incorporated
Counts Gary W
Goodrich and Rosati
Le Long V.
Sonsini Wilson
LandOfFree
Diagnostic markers of stroke and cerebral injury and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostic markers of stroke and cerebral injury and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic markers of stroke and cerebral injury and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3973311